. Author manuscript; available in PMC: 2016 Jun 3.

Published in final edited form as: Hepatology. 2011 Jan 10;53(2):389–395. doi: 10.1002/hep.24068

Table 2.

Characteristics of the Patients

Characteristic	Value
n	238
Age, years	52 (41–62)
Male sex, n (%)	142 (59)
Body mass index, kg/m²	26 (24–28)
Genotype 2, n (%)	185 (78)
Genotype 3, n (%)	53 (22)
HCV RNA, log₁₀ IU/mL	5.7 (5.3–6.0)
Alanine aminotransferase, IU/mL	59 (31–117)
Baseline Hb, g/dL	14.0 (13.0–15.0)
Baseline creatinine, μmol/L	0.87 (0.74–1.0)
METAVIR F3-F4, n (%)	48 (20)
RBV dose, mg/kg	15 (13.5–16.7)
Need for RBV dose reduction, n (%)
12-week treatment	11/109 (10)^*
24-week treatment	24/129 (19)

Data are presented as medians and 25th and 75th percentiles unless otherwise specified.

P = 0.06.